 |
7 Diseases |  |
13 Trials |
|
13 Trials |  |
1459 News |  |
| «12345678910111213...1617» |
- | Ajovy (fremanezumab-vfrm) / Teva
Journal, HEOR, Real-world evidence, Real-world: Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response. (Pubmed Central) - Mar 13, 2024
Patients with certain migraine comorbidities, potential AMO, and/or UPMPR in a real-world setting had reduced migraine-related medication use, HCRU, and costs following initiation of fremanezumab. Graphical abstract available for this article.
- The Effect of Applying a Demand Forecasting Model to Assess the Accuracy of Inventory Management in a Specialty Pharmacy () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_424;
The ARIMA model accurately forecasted the demand for nine medications, demonstrating either high accuracy or reasonable precision. Therefore, employing data-driven analytical methods appears to be a good option to demand forecasting compared to reliance on pharmacists
- Determinants of Innovative Drugs' Adoption: Evidence from Lithuania () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_402;
Institutional factors and price play a critical role in defining the speed of innovation diffusion in healthcare. Also, data suggests potential geographically defined inequality of Lithuanian doctors
- Ajovy (fremanezumab-vfrm) / Teva
A Prospective, Observational Study to Evaluate the Long-term Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3919;
No new safety findings in patients treated with fremanezumab were detected. With the current interest in the effects of CGRP pathway targeted medications on BP, measurements of BP should be encouraged as part of a routine migraine office visit.
- Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
Real-world Effectiveness of Intravenous Eptinezumab in Patients with Chronic Migraine and Previous Subcutaneous Preventive Migraine Treatment (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3916;
All patients (94/94) self-reported prior preventive therapy with 89% (84/94) reporting prior subcutaneous anti-CGRP mAb use (i.e., fremanezumab, galcanezumab, or erenumab). This real-world, patient survey showed that patients with prior exposure to subcutaneous anti-CGRP mAbs had high overall satisfaction with the effectiveness of eptinezumab treatment regardless of the number and type of previous therapies used.
- Ajovy (fremanezumab-vfrm) / Teva
Efficacy and Safety of Fremanezumab in Patients with Migraine and Obesity: Post Hoc Analysis of the Phase 3 HALO-LTS and FOCUS Clinical Trials (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3913;
P3
This analysis demonstrates that fremanezumab is efficacious and well tolerated over 6 months in patients with both migraine and obesity, consistent with outcomes from other pivotal fremanezumab studies. These data support the use of fremanezumab for migraine prevention in a wide population of patients.
- Ajovy (fremanezumab-vfrm) / Teva
Measurement and Modeling of Peripherally Administered Anti-CGRP Monoclonal Antibody in CSF and Brain of Healthy Volunteers (Colorado Convention Center | Bluebird 1B) - Mar 8, 2024 - Abstract #AAN2024AAN_3800;
These data support the use of fremanezumab for migraine prevention in a wide population of patients. The presented data affirms the potential for fremanezumab to access the CNS and engage its target.
- The Safety and Efficacy of Dual Calcitonin Gene-related Peptide Therapies for Migraine Treatment (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3206;
The observed reduction in headache severity and frequency suggests a dual blockade is beneficial for migraine symptom control in selected patients. Safety regarding this treatment option is also supported by these findings; specifically, the small molecule antagonists appear to be the safest option to include in dual regimens.
- Analysis of Calcitonin Gene-Related Peptide Receptor Monoclonal Antibody and Antagonist Usage and Medication Switch Profile from a Tertiary Care Facility (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3008;
We describe the CGRP mAb and gepant medication usage and switch profiles at JHC. Further investigation into the reason for the switch and its effect on headache outcomes remains to be conducted.
- Qulipta (atogepant) / AbbVie
Benefit-Risk Assessment Based on Number Needed to Treat and Number Needed to Harm: Atogepant vs Calcitonin Gene (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3006;
The base-case analysis included data from core studies of atogepant 60 mg, erenumab 70 mg and 140 mg, galcanezumab 120 mg, eptinezumab 100 mg and 300 mg, and fremanezumab 225 mg and 675 mg. Atogepant demonstrated a favorable benefit-risk profile, with NNT and NNH values comparable with those of CGRP mAbs across all scenarios.
- Qulipta (atogepant) / AbbVie
Real-world Switching Rates of Atogepant Are Lower than CGRP Monoclonal Antibodies (mAbs) in Patients with Migraine Using Claims Database (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2727;
Patients were excluded if they had ?1 claim for atogepant, rimegepant, BOTOX for migraine, or a CGRP mAb in the 12 months preceding the index date...At 12 months follow-up, 13.4% of atogepant users and 21.1% of CGRP mAb users (23.1% eptinezumab, 26.5% erenumab, 19.6% fremanezumab, 18.4% galcanezumab) initiated a different branded preventive. Compared with atogepant users, CGRP mAb users were significantly more likely to switch to another branded preventive treatment within 1 year of treatment initiation.
- Ajovy (fremanezumab-vfrm) / Teva
6-month Real-world Effectiveness of Fremanezumab in Patients with Migraine who Switched from Another mAb Targeting the CGRP Pathway (Subgroup Analysis from FINESSE) (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2725;
In this interim analysis of the FINESSE non-interventional study, 38.6% of anti-CGRP pathway mAb-non-responders benefit (?50% response) from switching to fremanezumab. These results suggest that switching to fremanezumab may be a promising option for patients experiencing inadequate efficacy or poor tolerability with prior other anti-CGRP pathway mAb use.
- Ajovy (fremanezumab-vfrm) / Teva
Fremanezumab Effectiveness and Tolerability in Clinical Routine: Interim Real-world Data of the Observational FINESSE Study (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2722;
In this interim analysis of FINESSE, 53.8% of patients achieved the primary endpoint, and reductions in MMD, disability scores and acute medication use were observed at 6 and 12 months of treatment. Tolerability data were consistent with known safety profile.
- Reasons for Discontinuation of Medical Management in Refractory Idiopathic Intracranial Hypertension (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2471;
Our study results suggest that medical management available for IIH may not be suitable for all patients, and many may discontinue the medication due to adverse effects or no improvement in symptoms. IIH patients refractory to medical management are a challenging sub-group requiring invasive and surgical diagnostic and treatment modalities.
- | Ajovy (fremanezumab) / Otsuka, Teva
Journal: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study. (Pubmed Central) - Mar 7, 2024
This RWE study documents that long-term fremanezumab treatment is highly effective and remarkably well tolerated in subjects with HFEM or CM with multiple (>?3) therapeutic failures, even in the presence of concomitant medication overuse, psychiatric comorbidities, or both. The effectiveness-to-tolerability ratio appears to be better in RWE than in RCTs.
- || Review, Journal, HEOR: Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario. (Pubmed Central) - Mar 7, 2024
In fact, all extracted studies showed a protective risk factor exposure in monthly migraine days reduction for all the anti-CGRP mAbs, whereas the cost analysis showed that using eptinezumab, in a quarter there is a cost saving of at least $425 per patient, compared with the other anti-CGRP mAbs. With equal efficacy and equal safety, anti-CGRP mAbs should be prescribed also regard to the cost established at the negotiation, making sure to guarantee the best treatment to the patients, but at the same time impacting as little as possible to the healthcare services resources.
- || Review, Journal: Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence. (Pubmed Central) - Feb 26, 2024
Eptinezumab lacked sufficient evidence regarding its impact on depression and anxiety...Galcanezumab and erenumab appear to be more effective in improving concurrent depressive and anxiety symptoms in migraine patients than fremanezumab...Further research is needed to fully understand the impact of CGRP antagonists on mental health disorders associated with migraines. These findings have implications for enhancing the overall well-being and quality of life in individuals with migraines and comorbid psychiatric conditions.
- ||| Journal, Adverse events, Adverse drug reaction: Cardiovascular Adverse Drug Reactions of Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies for Migraine Prevention: An Analysis from the European Spontaneous Adverse Event Reporting System. (Pubmed Central) - Feb 25, 2024
However, hypertension with ERE, atrial fibrillation and myocardial infarction with GMB, as well as pallor, deep vein thrombosis, hot flush, and palpitations with FMB were not reported in the Summary of Product Characteristics (SmPCs). Considering this, more post-marketing analyses are needed to improve knowledge on the CV safety profiles of anti-CGRP-mAbs, especially for the last approved medication, EPT.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Observational data, Retrospective data, Journal: Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients. (Pubmed Central) - Feb 24, 2024
this retrospective study comes out in favor of both significant efficacy and safety of anti-CGRP and anti-CGRP receptors mAbs in migraine patients. Further methodologically stronger studies are necessary to validate our observation.
- | Retrospective data, Journal: Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study. (Pubmed Central) - Feb 23, 2024
Fremanezumab was not included due to unavailability in the UAE...The safety of switching between CGRP classes was well observed, as any adverse events presented before the class switch did not lead to the discontinuation of treatment following the later switch. The findings of this study suggest that switching between different classes of CGRP mAbs is a potentially safe and clinically viable practice that may have some applications for those experiencing side effects on their current CGRP mAb or those witnessing suboptimal response.
- ||| Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal, Adverse events: Drug-related side effects and adverse reactions in the treatment of migraine: a bibliometric and visual analysis. (Pubmed Central) - Feb 21, 2024
Furthermore, it is imperative to enhance the assessment of clinical trial outcomes, consistently monitor the efficacy and safety of prominent drugs such as Erenumab and Fremanezumab. There is a need for further evaluation of acute and preventive treatments tailored to different populations and varying types of migraine.
- ||||| Ajovy (fremanezumab-vfrm) / Teva
Enrollment closed: A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age (clinicaltrials.gov) - Feb 16, 2024
P3, N=230, Active, not recruiting, Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
There is a need for further evaluation of acute and preventive treatments tailored to different populations and varying types of migraine. Recruiting --> Active, not recruiting
- | Ajovy (fremanezumab-vfrm) / Teva, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial completion date, Trial primary completion date, Monotherapy: COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study (clinicaltrials.gov) - Feb 15, 2024
P4, N=50, Recruiting, Sponsor: Chicago Headache Center & Research Institute
Recruiting --> Active, not recruiting Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Oct 2024
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Effect of anti-CGRP-targeted therapy on migraine aura: Results of an observational case series study. (Pubmed Central) - Feb 13, 2024
Conversely, these antibodies are able to counteract, via their peripheral mechanisms of action, the sensitization of the trigemino-vascular pathway which is triggered by CSD. This aforementioned might explain why in our patients, migraine aura attacks remained unchanged in their frequencies, but the headache phases were either reduced or absent.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon
Retrospective data, Journal: Treatment patterns of galcanezumab versus standard of care preventive migraine medications over 24 months: a US retrospective claims study. (Pubmed Central) - Feb 9, 2024
Significantly greater proportions of patients who initiated galcanezumab versus SOC medications switched to fremanezumab (p?<?0.001) and onabotulinumtoxinA (p?=?0.016). Patients who initiated galcanezumab for migraine prevention had higher treatment adherence and persistence compared with those who initiated SOC medications after 24-month follow-up.
- | Ajovy (fremanezumab) / Otsuka, Teva
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway. (Pubmed Central) - Feb 2, 2024
Patients who initiated galcanezumab for migraine prevention had higher treatment adherence and persistence compared with those who initiated SOC medications after 24-month follow-up. Specific antibodies
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab) / Otsuka, Teva
Journal: Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study. (Pubmed Central) - Jan 25, 2024
Further studies are required to determine treatment options for patients with continuous headache. Poor agreement between outcomes at 3 and 12 months highlights the need to assess some patients at later timepoints.
- ||| Journal, Adverse events, Real-world evidence, Real-world: Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system. (Pubmed Central) - Jan 24, 2024
In addition, there are new AEs that were not listed in the drug instructions but occurred concurrently with multiple drugs, such as Raynaud's phenomenon, weight increase, menstrual disorders, throat tightness, and paraesthesia oral. Common AE signals of the four anti-CGRP mAbs and new AE signals were found to provide a reference for clinical drug selection in clinical practice.
- | Ajovy (fremanezumab) / Otsuka, Teva
Journal: Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine. (Pubmed Central) - Jan 23, 2024
Fremanezumab given for at least 6-9 months may exert neuromodulatory effects in the migraine brain. These effects could result both in the inhibition of migraine chronification, but also in the diminishing of the magnitude of migraine-associated symptoms, mostly in responders and in partial non-responders.
- || Vyepti (eptinezumab) / Teva, Lundbeck, Ajovy (fremanezumab) / Otsuka, Teva
Retrospective data, Review, Journal: Efficacy and Safety of Anti-CGRP Monoclonal Antibodies in Prevention of Chronic Migraine: A Bayesian Network Meta-analysis. (Pubmed Central) - Jan 22, 2024
Galacenequmab was better at reducing MMD. Further studies are needed to evaluate the long-term safety, efficacy, and use of mAbs in migraine patients.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Retrospective data, Journal, Real-world evidence, Real-world: Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a (Pubmed Central) - Jan 22, 2024
Further studies are needed to evaluate the long-term safety, efficacy, and use of mAbs in migraine patients. In this real-world setting, anti-CGRP preventives reduced MDM persistently and had similar and large effect sizes on MDM reduction; however, clinical and genetic factors influenced response.
- | New trial: Migraine Medication Effects on Urinary Symptoms (clinicaltrials.gov) - Jan 18, 2024
P=N/A, N=200, Not yet recruiting, Sponsor: The Cleveland Clinic
- | Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Observational data, Journal, Real-world evidence, Real-world: No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study. (Pubmed Central) - Jan 16, 2024
There was no wearing-off in treatment responders, which is in alignment with premarketing data from placebo-controlled phase III studies. These data suggest that patients should be informed upfront that no wearing-off effect is expected because anxiety for attacks at the end of the month per se may generate migraine attacks.
- | Retrospective data, Journal, Real-world evidence, Real-world: Comparison of Treatment Patterns in Patients with Migraine Initiating Calcitonin Gene-Related Peptide Monoclonal Antibodies: A Retrospective Real-World US Study. (Pubmed Central) - Jan 15, 2024
Similar results were observed for 6-month follow-up cohorts. Patients with migraine who initiated treatment with galcanezumab showed higher persistence and lower treatment discontinuation rates than those initiating either fremanezumab or erenumab.
- ||||| Ajovy (fremanezumab) / Otsuka, Teva
Enrollment change: A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Patients 6 to 17 Years of Age (clinicaltrials.gov) - Dec 27, 2023
P3, N=278, Recruiting, Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Patients with migraine who initiated treatment with galcanezumab showed higher persistence and lower treatment discontinuation rates than those initiating either fremanezumab or erenumab. N=418 --> 278
- || Ajovy (fremanezumab) / Otsuka, Teva, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap, Aimovig (erenumab-aooe) / Amgen, Novartis
Review, Journal: Treatment Options for Posttraumatic Headache: A Current Review of the Literature. (Pubmed Central) - Dec 22, 2023
A randomized crossover study of 40 patients with persistent PTH found that onabotulinum toxin-A decreased cumulative number of headaches/week by 43.3% in the treatment group and increased by 35.1% among placebos...New studies indicate promise in improving clinically important outcomes of PTH. However, more research is necessary to determine the optimal treatment and whether combining pharmacologic and nonpharmacologic treatment versus a single modality is more effective.
- |||| Ajovy (fremanezumab-vfrm) / Teva
New P4 trial: Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 (clinicaltrials.gov) - Dec 18, 2023
P4, N=72, Not yet recruiting, Sponsor: Brigham and Women's Hospital
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Observational data, Journal: Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study. (Pubmed Central) - Dec 13, 2023
However, more research is necessary to determine the optimal treatment and whether combining pharmacologic and nonpharmacologic treatment versus a single modality is more effective. Our findings suggest that anti-CGRP mAbs are highly effective in migraine with aura, both in reducing mean monthly aura days and mean monthly days with headache.
- || Retrospective data, Review, Journal: Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis. (Pubmed Central) - Dec 11, 2023
The absolute differences in the number of headache/migraine days are, at best, modest. No evidence was found to determine the relative effectiveness of the six included drugs with other oral preventive medications.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal. (Pubmed Central) - Dec 9, 2023
In our study, the three anti-CGRP mAbs presented a similar response, with no significant differences, during the first year of therapy, the suspension period, and 3 months after the drug reprisal. The response rate during the 1-month suspension period in chronic migraineurs may be higher with galcanezumab.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Retrospective data, Journal: Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study. (Pubmed Central) - Dec 5, 2023
Conclusion CGRP-mAb has been suggested as a preventive treatment for patients with MOH. Further investigation of the long-term efficacy of CGRP-mAb for MOH is needed.
- | Ajovy (fremanezumab) / Otsuka, Teva
Retrospective data, Journal, HEOR, Real-world evidence, Real-world: Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study. (Pubmed Central) - Nov 27, 2023
Fremanezumab is effective and safe for migraine prevention in Japan. Fremanezumab also improved migraine-associated symptoms in half of the patients.
- | Ajovy (fremanezumab) / Otsuka, Teva
Journal: Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study. (Pubmed Central) - Nov 24, 2023
This study provides evidence for the real-world effectiveness of fremanezumab in treating both high-frequency episodic migraine and chronic migraine, with meaningful and sustained improvements in multiple migraine-related variables. No new safety issue was identified.
- || Ajovy (fremanezumab) / Otsuka, Teva
Observational data, P4 data, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. (Pubmed Central) - Nov 21, 2023
No new safety issue was identified. PEARL interim results support the effectiveness and safety of fremanezumab for migraine prevention in a real-world population across several European countries.Trial registration: encepp.eu: EUPAS35111.
- | Ajovy (fremanezumab) / Otsuka, Teva
Journal: Response to letter: "Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule" by Suzuki et al. (Pubmed Central) - Nov 19, 2023
PEARL interim results support the effectiveness and safety of fremanezumab for migraine prevention in a real-world population across several European countries.Trial registration: encepp.eu: EUPAS35111. No abstract available
- | Ajovy (fremanezumab) / Otsuka, Teva
Retrospective data, Journal: Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis. (Pubmed Central) - Nov 13, 2023
No abstract available The NNT, NNH, and LHH for quarterly and monthly fremanezumab compare favorably with those for traditional oral preventive medications, including topiramate, valproate, and propranolol.
- || Review, Journal: Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review. (Pubmed Central) - Oct 24, 2023
This included the four Food and Drug Administration (FDA)-approved medications erenumab, galcanezumab, fremanezumab, and eptinezumab...The results further imply that combination treatment with CGRP antibodies and onabotulinumtoxinA may enhance the prevention of migraine in adults...Additionally, the study discovered considerable variances in effectiveness amongst various groups. However, further investigation is required to establish the best time and dosage and the effect of patient characteristics on the effectiveness and safety of these medications.
- | Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. (Pubmed Central) - Oct 17, 2023
Anti-CGRP (ligand or receptor) monoclonals lead to improvement of depressive symptoms in individuals with migraine, independent of migraine reduction. Depression may predict treatment response to erenumab but not to fremanezumab.
- | Emgality (galcanezumab) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy. (Pubmed Central) - Oct 13, 2023
Overall, findings seem to indicate a favorable tolerability and effectiveness profile. Further studies are warranted to better establish the long-term comparative effectiveness, safety, and cost effectiveness of anti-CGRP mAbs compared to other preventive medications.
- | botulinum neurotoxin type A gel formulation (RT001) / Revance Therap, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Retrospective data, Journal, Real-world evidence, Real-world: Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies. (Pubmed Central) - Oct 4, 2023
The data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvieclinicaltrials.com/hcp/data-sharing/.